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Despite the necessary and major goal of containment 
of artemisinin resistance in Plasmodium falciparum,1–4 
not all malaria is caused by P falciparum and outside 
of Africa the greatest malaria burden is attributable 
to Plasmodium vivax.1 In The Lancet Infectious Diseases, 
Ric Price and colleagues5 report a systematic review 
of the resistance of P vivax to chloroquine, examining 
published studies from 1960 to 2014. They conclude 
that chloroquine-resistant P vivax is now present across 
most of vivax-endemic regions. In addition to containing 
their high-quality analysis, their Article proposes a set of 
methods to explore resistance to antimalarial drugs in 
vivax malaria and highlights a surprising scarcity of data 
and methods available to work on P vivax.
post-exposure prophylaxis to more than 10 000 people. 
In Europe, active vaccination against hepatitis A is 
currently recommended mainly for travelers visiting 
countries endemic for hepatitis A virus. International 
travel is a risk factor, accounting for about a third of 
cases in Austria and Germany. In 2013, 80 cases of 
hepatitis A were statutorily reported in Austria and 
779 in Germany, of which 25 in Austria and 278 in 
Germany were imported infections. By contrast with 
Germany, the Austrian national vaccination plan since 
2008 has included a recommendation of hepatitis A 
virus vaccination for all seronegative food handlers in 
food production and gastronomy companies. 
According to Sprenger, the recent foodborne 
outbreaks of hepatitis A in Europe raise the question 
whether the member states should consider options 
for even broader vaccination recommendations 
against hepatitis A.9 However, the ultimate aim should 
be food product safety—ie, to secure the absence of 
hepatitis A virus from food. Viral contamination of 
food can occur anywhere in the production process, 
but most foodborne viral infections can be traced 
back to infected people who handled food that is not 
heated or otherwise treated afterwards.10 Experimental 
studies have shown that the virus can be transferred 
from contaminated hands to food and surfaces.11 
Appropriate and regular hand hygiene practices are 
the mostly eﬀ ective measure to prevent transmission 
of hepatitis A virus. Ensuring adequate hygiene in the 
countries producing the food will be a major challenge 
in the endeavor to prevent foodborne hepatitis A. In the 
meantime, physicians and public health oﬃ  cers should 
consider hepatitis A infections as possibly foodborne until 
proven otherwise. Routine collection and preservation of 
serum and stool samples from all patients with hepatitis 
A within 28 days of the date of symptom onset would 
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improve detection and control outbreaks. In this way, the 
treating physician can have a paramount role in disease 
prevention in high-income countries.
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Many national control programmes are quite 
insensitive to concerns about vivax elimination in 
the face of the threat of falciparum. However, vivax, 
and the threat of resistance in that organism, needs 
to be considered in its own right. The P vivax lifecycle 
has important differences to that of P falciparum, 
which are expected to slow down the development of 
resistance to chloroquine.6 The parasite stays as latent 
forms (hypnozoites) in the liver, from which regular 
relapses can occur. Treatment with chloroquine alone 
cannot prevent relapses and hence the interest in 
hypnozoiticidal drugs such as primaquine. Vivax can 
produce gametocytes (stages that are infectious 
to mosquitoes) rapidly after emergence from the 
liver and invasion of the blood. This contrasts with 
falciparum, which not only does not have latent 
liver stages, but also takes a minimum of 10 days 
to generate infectious gametocytes in the blood.7 
Both these lifecycle differences should expose 
vivax parasites to less selection pressure from drug 
treatment. However, vivax parasites might have been 
exposed to sublethal concentrations of chloroquine 
after treatment for falciparum malaria during 
coinfection; treatment of falciparum cases in Thailand 
was often followed by a clinical case of vivax malaria.8 
Now that chloroquine is no longer the first-line drug 
for treating falciparum malaria, this collateral effect 
will be alleviated. Thus, the probability of the spread 
of resistance is expected to be lower for vivax than 
that for falciparum. Lower but not null, and this risk 
must be taken into account when considering vivax 
national treatment policies. 
Obstacles speciﬁ c to addressing of P vivax 
chloroquine resistance need to be overcome: it is 
very diﬃ  cult to do standardised in-vitro culture 
(and therefore have a reproducible phenotype of 
drug sensitivity); it is impossible to distinguish 
between relapse and recrudescence; we have little 
information on the population genetic structure 
of P vivax (gene ﬂ ow, selﬁ ng rate, etc); and so far no 
molecular marker of resistance has been proposed 
for large epidemiological studies. The absence of 
molecular markers is, of course, a major obstacle for 
use in the assessment of the spread of resistance and, 
thus, optimisation of thera peutic strategies. A key 
step for the identiﬁ cation of a molecular marker is 
development of a clear-cut phenotype of resistance. 
Price and colleagues propose parasite clearance time 
as a proxy to study antimalarial resistance. Indeed, 
accurate characterisation of this clearance time would 
enable diﬀ erentiation of clinical resistance from 
relapse.9 
There has been much conjecture on whether P vivax 
and P falciparum aﬀ ect one another and thus whether 
targeting one species might lead to the emergence 
of the other.10,11 Focus is now on the ﬁ ght against 
P falciparum, which seems to have had little eﬀ ect 
on the vivax burden.1 For public health care, vivax 
malaria must be considered as a disease distinct 
from falciparum malaria,12,13 and will beneﬁ t from 
a dedicated control programme strategy. Malaria 
elimination will not be able to ignore vivax, which 
should no longer be the least of our worries.
*Frédéric Ariey, Richard E Paul
Genetics and Genomics of Insect Vectors Unit (FA) and 
Functional Genetics of Infectious Diseases Unit (REP), Institut 
Pasteur, Paris 75724, France
frederic.ariey@pasteur.fr
We declare no competing interests.
Copyright © Ariey et al. Open Access article distributed under the terms of CC BY.
1 WHO. World Malaria Report 2013. http://www.who.int/malaria/
publications/world_malaria_report_2013/en/ (accessed Aug 24, 2014).
2 Dondorp AM, Nosten F, Poravuth Y, et al. Artemisinin resistance in 
Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455–67.
3 Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of 
artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 
505: 50–55. 
4 Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin 
resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 
371: 411–23.
5 Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. 
Prevalence of chloroquine-resistant Plasmodium vivax: a systematic 
review. Lancet Infect Dis 2014; published online Sept 9. http://dx.doi.
org/10.1016/S1473-3099(14)70855-2.
6 Garnham PCC. Malaria parasites and other haemosporidia. Oxford: 
Blackwell, 1966: 1132. 
7 Talman AM, Domarle O, McKenzie FE, et al. Gametocytogenesis: the 
puberty of Plasmodium falciparum. Malar J 2004; 3: 24.
8 Looareesuwan S, White NJ, Chittamas S, et al. High rate of Plasmodium 
vivax relapse following treatment of falciparum malaria in Thailand. 
Lancet 1987; 2: 1052–55.
9 Pukrittayakamee S, Imwong M, Looareesuwan S, et al. Therapeutic 
responses to antimalarial and antibacterial drugs in vivax malaria. 
Acta Trop 2004; 89: 351–56.
10 Sattabongkot J, Tsuboi T, Zollner GE, et al. Plasmodium vivax 
transmission: chances for control? Trends Parasitol 2004; 20: 192–98.
11 Snounou G, White NJ. The co-existence of Plasmodium: sidelights from 
falciparum and vivax malaria in Thailand. Trends Parasitol 2004; 
20: 333–39.
12 Vogel G. The forgotten malaria. Science 2013; 342: 684–687.
13 Cotter C, Sturrock HJ, Hsiang MS, et al. The changing epidemiology of 
malaria elimination: new strategies for new challenges. Lancet 2013; 
382: 900–11. 
Gl
ad
de
n 
W
ill
is,
 V
isu
al
s U
nl
im
ite
d/
Sc
ie
nc
e 
Ph
ot
o 
Li
br
ar
y
